ZyVersa Therapeutics prices 2.1M shares at 95c in private placement

ZyVersa Therapeutics (ZVSA) has entered into a securities purchase agreement with a single healthcare-focused U.S. institutional investor for the purchase and sale of 2,105,265 shares of common stock and warrants to purchase up to 2,105,265 shares of common stock at an effective combined price of $0.95 per share and common warrant for aggregate gross proceeds of approximately $2M, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $1.00 per share, will be exercisable immediately upon shareholder approval and will expire five years from the initial exercise date. The closing of the offering is expected to occur on or about March 7, 2025, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering for general working capital. A.G.P./Alliance Global Partners is acting as the sole placement agent in connection with the transaction.